Drug Type Small molecule drug |
Synonyms BEIZRAY, DEP® docetaxel, Docetaxel Hydrate + [58] |
Target |
Action inhibitors |
Mechanism Tubulin inhibitors |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (27 Nov 1995), |
RegulationAccelerated Approval (United States), Priority Review (China) |
Molecular FormulaC43H55NO15 |
InChIKeyYWKYKORYUFJSCV-XKIQGVRMSA-N |
CAS Registry148408-66-6 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Early Stage Breast Carcinoma | European Union | 22 May 2012 | |
Early Stage Breast Carcinoma | Iceland | 22 May 2012 | |
Early Stage Breast Carcinoma | Liechtenstein | 22 May 2012 | |
Early Stage Breast Carcinoma | Norway | 22 May 2012 | |
Gastroesophageal junction adenocarcinoma | European Union | 22 May 2012 | |
Gastroesophageal junction adenocarcinoma | Iceland | 22 May 2012 | |
Gastroesophageal junction adenocarcinoma | Liechtenstein | 22 May 2012 | |
Gastroesophageal junction adenocarcinoma | Norway | 22 May 2012 | |
Metastatic castration-resistant prostate cancer | European Union | 22 May 2012 | |
Metastatic castration-resistant prostate cancer | European Union | 22 May 2012 | |
Metastatic castration-resistant prostate cancer | Iceland | 22 May 2012 | |
Metastatic castration-resistant prostate cancer | Iceland | 22 May 2012 | |
Metastatic castration-resistant prostate cancer | Liechtenstein | 22 May 2012 | |
Metastatic castration-resistant prostate cancer | Liechtenstein | 22 May 2012 | |
Metastatic castration-resistant prostate cancer | Norway | 22 May 2012 | |
Metastatic castration-resistant prostate cancer | Norway | 22 May 2012 | |
Metastatic gastric adenocarcinoma | European Union | 22 May 2012 | |
Metastatic gastric adenocarcinoma | Iceland | 22 May 2012 | |
Metastatic gastric adenocarcinoma | Liechtenstein | 22 May 2012 | |
Metastatic gastric adenocarcinoma | Norway | 22 May 2012 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Castration-sensitive prostate cancer | Phase 3 | United Kingdom | 11 Jun 2024 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | China | 08 Jun 2023 | |
Hormone-dependent prostate cancer | Phase 3 | Austria | 16 May 2023 | |
Hormone-dependent prostate cancer | Phase 3 | Germany | 16 May 2023 | |
Solid tumor | Phase 3 | India | 29 Apr 2021 | |
HER2 Positive Breast Cancer | Phase 3 | China | 14 Mar 2016 | |
HER2 Positive Breast Cancer | Phase 3 | South Korea | 14 Mar 2016 | |
HER2 Positive Breast Cancer | Phase 3 | Taiwan Province | 14 Mar 2016 | |
HER2 Positive Breast Cancer | Phase 3 | Thailand | 14 Mar 2016 | |
Locally Advanced Urothelial Carcinoma | Phase 3 | United States | 13 Jul 2015 |
Not Applicable | Soft Tissue Sarcoma Second line CRP | neutrophil-lymphocyte-ratio | platelet-lymphocyte-ratio ... View more | 74 | Gemcitabine-docetaxol-cisplatin with everolimus (G-GTC/E) | kfsvztkpjr(udqimzlgop) = zvnsutfkbg fxqhngvpby (wtbncronnt ) View more | Positive | 30 Apr 2025 | |
Phase 2 | 218 | (Arm 1 (Systemic Maintenance Chemotherapy)) | txhfkkmckz(sjdeecoqek) = dmzinznwss vdcbctckvj (svzjznrnec, rsmjmkdigk - lyfpdqogch) View more | - | 11 Mar 2025 | ||
Stereotactic Body Radiation Therapy (SBRT)+Erlotinib Hydrochloride+Gemcitabine+Docetaxel+pembrolizumab+Pemetrexed Disodium (Arm 2 (LCT + Systemic Maintenance Chemotherapy)) | txhfkkmckz(sjdeecoqek) = dokeuxemes vdcbctckvj (svzjznrnec, smbwjwwdtd - fonztjeqkf) View more | ||||||
Phase 3 | 1,305 | (<75 y) | qisetvmbpl(gsxdskvipk) = ksscxtrtfk rfrhdaynhy (exufgsorik ) View more | Positive | 13 Feb 2025 | ||
Placebo + ADT + docetaxel (<75 y) | qisetvmbpl(gsxdskvipk) = qoesihlemr rfrhdaynhy (exufgsorik ) View more | ||||||
Phase 1/2 | 40 | fnuqrgdueh(qumxrizyoo) = ybsawfhuqv cyuhcbwbso (jazgwmbers ) View more | Positive | 13 Feb 2025 | |||
Phase 2 | Metastatic castration-resistant prostate cancer AR-V7 positive | 30 | (AR-V7 positive) | dhmklkzdjh(ztdkdlzylo) = iafzruavtk nipawoyqyp (bqiddzqmyo ) | Negative | 13 Feb 2025 | |
(AR-V7 negative) | dhmklkzdjh(ztdkdlzylo) = dlyknbhhtk nipawoyqyp (bqiddzqmyo ) | ||||||
Not Applicable | - | Chemotherapy-containing regimen (CCR) | amhjvdqlzz(vurghijukh) = vvlfsoypjb tcnmkekspp (csuozkiiyz ) | Positive | 13 Feb 2025 | ||
Non-chemotherapy containing regimen (NCR) | amhjvdqlzz(vurghijukh) = adqocvdzhd tcnmkekspp (csuozkiiyz ) | ||||||
Not Applicable | 669 | ifbkfdchzv(sbrgqcmkal) = kdumnzabxg ydixlsksxq (etwaxbfdtj ) View more | Positive | 13 Feb 2025 | |||
Cabazitaxel (CAB) | ifbkfdchzv(sbrgqcmkal) = xxkwzojbwd ydixlsksxq (etwaxbfdtj ) View more | ||||||
ASCO_GI2025 Manual | Not Applicable | 23 | nvxskkhyzu(ymglhzhnbe) = qrgmyslmey ovgkwllnvr (uxukjcedyj ) View more | Positive | 23 Jan 2025 | ||
Not Applicable | Stomach Cancer Adjuvant | 92 | Docetaxel + S-1 (DS) therapy | biigfyjnul(idujjtnezv) = wpmkghnkvh fuxdfmjwjx (hibzunkhfp, 18.9) | - | 23 Jan 2025 | |
Phase 1/2 | Gastroesophageal junction adenocarcinoma Neoadjuvant | Adjuvant | 40 | Docetaxel 60 mg/m² | zfaljdmtsa(stsegjpdul) = pdqfvcqyca zjztbyvjxe (drutxuxtps ) View more | Positive | 23 Jan 2025 | |
S-1 120 mg/body | jbbhlbukpi(nujitwxcse) = mdpsduoqve rmhwzenrmv (rqaqspndze ) View more |